Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Trimedyne

This article was originally published in The Gray Sheet

Executive Summary

Trimedyne: Laser firm's Cardiodyne subsidiary files an IDE to commence clinical trials of its holmium-based myocardial laser revascularization system to treat patients suffering from severe angina and myocardial ischemia who either are unresponsive to, or not suitable for, drug therapy and who have failed coronary artery bypass surgery and/or percutaneous transluminal coronary angioplasty. The system features an 8-watt SuperPulse holmium laser, AutoFire interface and ChannelMaker fiber-optic needle device. AutoFire monitors a patient's electrocardiogram and, based on data obtained, automatically creates a channel in the heart wall when the left ventricle is full of blood...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009128

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel